Press Releases :: Alzamend Neuro, Inc. (ALZN)

NASDAQ: ALZN

Jul 28, 2021 3:07pm EDT

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Disease

Jul 23, 2021 6:30am EDT

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

Jul 12, 2021 6:00am EDT

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 01, 2021 6:30am EDT

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer’s Disease

Jun 17, 2021 4:30pm EDT

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million

Jun 14, 2021 5:49pm EDT

Alzamend Neuro Announces Pricing of Initial Public Offering

Mar 12, 2021 6:41am EST

Alzamend Neuro®, Inc. announces an agreement to sell $10,000,000 of its securities to Digital Power Lending LLC, a subsidiary of Ault Global Holdings, Inc.

Dec 29, 2020 5:44pm EST

Alzamend Neuro®, Inc. Announces Confidential Submission of Draft Registration Statement Relating to the Proposed Initial Public Offering of Its Common Stock

Nov 16, 2020 9:00am EST

Alzamend Neuro®, Inc. Registration is Closing to Join the Shareholder and Investor Conference Call and Webcast Set for Tomorrow, November 17, 2020 to Provide Update and Plans for 2021

Nov 03, 2020 9:45am EST

Alzamend Neuro®, Inc. Announces Shareholder and Investor Conference Call and Webcast to Provide Update and Plans for 2021

rss_feed News RSS